Lostop

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lostop

Property Description
Active Ingredient Loratadine
Form Oral (Tablet, Syrup, ODT)
Pharmacological Class Second-Generation H₁-Antihistamine
Common Use Symptomatic relief of allergy
Origin Synthetic Tricyclic Derivative

Lostop: Definition and Pharmacological Classification

Lostop is a systemic anti-allergic agent belonging to the pharmacological class of second-generation Histamine H₁-Receptor Antagonists, commonly known as antihistamines. This medicine's primary purpose is the sustained, non-sedating relief of symptoms caused by allergic reactions throughout the body.

The classification as a second-generation compound, which utilizes the active ingredient Loratadine, is crucial because it indicates a specific advancement over older agents. Loratadine is a synthetic, tricyclic compound designed with limited ability to cross the blood-brain barrier. This design ensures the medication’s antagonistic action is focused on the peripheral H₁-receptors in the tissues, confirming its identity as a non-sedating option that provides long-acting relief. Second-generation antihistamines, like Loratadine, primarily antagonize peripheral H₁ receptors. This means the medicine works in the body to control allergies without making you drowsy.


Composition, Origin, and Available Forms

The active substance in Lostop is Loratadine, a chemically synthesized Azatadine derivative that is responsible for the medication's therapeutic effects. Lostop is a monotherapy product, meaning it contains only Loratadine as its active ingredient, combined with standard excipients for stability and delivery.

The medication is intended for the oral route of administration and is supplied in several convenient forms to meet varied patient needs, particularly catering to children (syrup, chewable tablet) and individuals with difficulty swallowing (ODT). These preparations include the standard tablet and oral solution (syrup), alongside specialized formats such as the chewable tablet and the orally disintegrating tablet (ODT). Loratadine is a non-sedating anti-allergic agent for the oral treatment of common allergy symptoms. This means the medicine is used for easing allergy-related discomfort.


General Purpose of Lostop

The general therapeutic purpose of Lostop is to mitigate discomfort caused by the release of histamine, the key inflammatory chemical responsible for allergic responses, often seen in typical seasonal allergy scenarios. This effect is achieved through the selective blockade of peripheral H₁-receptors in tissues. By preventing histamine from binding, Lostop effectively provides sustained control over common allergic manifestations, including sneezing, runny nose, itchy or watery eyes, and dermatological symptoms like urticaria.

Regulatory References

  1. NIH: Loratadine StatPearls

What side effects are possible with Lostop?

Possible Side Effects and Safety Information

The officially documented adverse reactions for Lostop (Loratadine) are categorized by frequency and the affected body system, aligning with regulatory standards from authorities like the EMA and FDA.


Frequency-Classified Adverse Reactions

The most frequently reported effects are classified as Common, defined as occurring in 1% to 10% of users. The following table summarizes the key adverse reactions across the regulatory frequency categories:

Classification Examples of Documented Reactions
Common Headache, Somnolence (Drowsiness/Tiredness), Fatigue, Dry mouth.
Uncommon Insomnia, Appetite increased.
Very Rare Anaphylaxis, Dizziness, Convulsions, Tachycardia, Hepatic function abnormal.

These reactions are organized into System-Organ Classes (SOCs) such as Nervous system disorders (e.g., Headache, Somnolence) and Gastrointestinal disorders (e.g., Dry mouth, Nausea). Other SOCs include Cardiac disorders and Hepatobiliary disorders.


Serious Adverse Reactions and Safety Constraints

Adverse reactions classified as Very Rare, such as Anaphylaxis and severe manifestations of Hepatic function abnormal, represent the serious events documented in regulatory labeling. The medicine's use is contraindicated in individuals with known hypersensitivity to Loratadine or any excipient. Furthermore, use requires caution in patients with severe hepatic impairment, where a lower initial dose is officially specified. In pediatric patients (aged 6–12 years), nervousness is also specifically listed as a common adverse reaction.

The official safety information structures the understanding of potential risk by formally classifying adverse reactions according to frequency and physiological system. This framework defines the expected profile, highlighting that the most common effects are generally non-severe while simultaneously documenting the potential for rare but serious events.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for a Lostop (Loratadine) overdose is strictly defined by documented manifestations and required emergency actions, providing clear guidance on when to seek assistance.


Documented Overdose Signs and Symptoms

Overdose situations are officially associated with specific clinical signs, most frequently including tachycardia (a rapid heart rate), headache, and pronounced somnolence (drowsiness). The regulatory documentation also reports an increased occurrence of anticholinergic symptoms following exposure to doses higher than the recommended amount. Serious outcomes, such as the potential for cardiac arrhythmias, may occur, necessitating close cardiac monitoring.


Required Emergency Actions

It is officially mandated that you seek immediate medical attention and contact a poison control center, doctor, or pharmacist without delay if an overdose is suspected. Treatment is strictly symptomatic and supportive, as no specific antidote is known. Procedures such as administering activated charcoal or gastric lavage may be considered by medical personnel to remove the unabsorbed substance. Due to the systemic nature of the drug, medical monitoring of the patient is required to be continued after initial emergency treatment.


Population-Specific Considerations

The risk of somnolence is noted to increase in elderly patients and those with hepatic or renal impairment following exposure to higher-than-recommended doses. Furthermore, regulatory information confirms that Loratadine and its metabolites are not removed by haemodialysis.

Therapeutic Uses of Lostop

What Lostop Treats: Main Uses and Benefits

Lostop (Loratadine) is a second-generation anti-allergic agent, generally used to provide effective, symptomatic relief across the key areas affected by allergic reactions. Its primary purpose is to help manage symptoms related to inflammatory or irritative states, which assists with maintaining functional stability.

Allergic Rhinitis and Urticaria

The medication is relevant for managing conditions involving recurrent or episodic manifestations, such as seasonal and perennial allergic rhinitis and urticaria (hives). It is used for managing symptom clusters that may become intense or disruptive, such as sneezing, runny nose (rhinorrhea), itchy/watery eyes, and skin itching (pruritus) that may become intense. This use contributes to easing the overall symptom load during periods of heightened symptoms.

Sustained, Non-Impairing Therapeutic Benefit

A key patient-oriented benefit is its support for long-acting symptomatic relief, which may assist with maintaining functional stability for up to a day without causing significant drowsiness. This supports general well-being during symptomatic phases, providing supportive relief that may help maintain functional stability during chronic or acute allergy episodes.


Quick Fact: Relief for Itchy Skin and Nasal Symptoms Lostop is applied in scenarios where additional management of discomfort is required to address both the bothersome nasal/ocular symptoms of hay fever and the intense itching associated with skin rashes.

Regulatory References

  1. NIH MedlinePlus overview on Loratadine

Eligibility and Restrictions for Use

Who can and cannot use Lostop: Official Regulatory Information

The eligibility profile for Lostop (Loratadine) is defined by official government documents regarding age, physiological status, and underlying health conditions.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and Adolescents (ge 12 years). Children aged 2 years and older. Older adults do not typically require a dose adjustment based on age alone.
Populations for whom use is not recommended Pregnancy and Lactation (Breastfeeding): Use is generally not recommended due to lack of established safety and excretion into breast milk. Children under 2 years of age: Efficacy and safety have not been established by regulators.
Populations for whom use is contraindicated Individuals with known hypersensitivity (allergy) to Loratadine or any excipients in the specific product formulation.

Condition-Specific Eligibility

Official labeling defines restricted use for certain populations. Patients with severe liver impairment are designated for restricted use and typically require an adjustment to the administration frequency. Use in patients with renal insufficiency requires caution. Specific oral formulations may be restricted for patients with Phenylketonuria (PKU) if they contain phenylalanine (aspartame), or for patients with hereditary sugar/lactose intolerance if the formulation contains those excipients.

Eligibility Classification Summary

Lostop is classified by regulators as Contraindicated for allergic individuals, Not Recommended for specific age and reproductive groups, and requiring Restricted Use for those with severe hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Lostop (Loratadine) is predominantly defined by pharmacokinetic patterns, as documented in official regulatory sources.

Pharmacokinetic and Exposure Alterations

Lostop is metabolized by the liver enzymes Cytochrome P450 (CYP) 3A4 and CYP2D6. Co-administration with known inhibitors of these enzymes results in documented increases in Loratadine exposure. Specific medicines that substantially increase the plasma concentrations (AUC and Cmax) of Loratadine and its metabolite include Ketoconazole, Erythromycin, and Cimetidine.

Regulatory documentation confirms that while these inhibitors significantly raise systemic exposure, controlled studies reported no associated clinically important changes in the safety profile, such as altered electrocardiographic parameters or increased somnolence, at recommended doses.

Substance and Food Interactions

Interacting Substance Documented Official Outcome
Food Increases systemic bioavailability (AUC) and delays the time to peak plasma concentration (Tmax).
Alcohol Clinical studies have not found a potentiation of psychomotor effects when administered concomitantly.
CNS Depressants Potential for additive pharmacodynamic effects resulting in increased drowsiness.

Administration Requirements and Population Notes

Loratadine administration must be discontinued for at least 48 hours before undergoing any allergy skin testing to prevent the antihistamine effect from interfering with the test results. Furthermore, patients with severe hepatic impairment or renal impairment (creatinine clearance leq 30 mL/min) are documented to have significantly increased Loratadine exposure.

Mechanism of Action

Lostop's mechanism is fundamentally defined by the inverse agonism of its active components, Loratadine and its major metabolite, Desloratadine, at the Histamine mathbfH1 Receptor ( H1-R). This molecular interaction stabilizes the H1-R in an inactive conformation, directly suppressing the signaling cascade initiated by the endogenous mediator, histamine. The drug is engineered for limited penetration of the Blood-Brain Barrier (BBB), restricting its action to peripheral tissues such as vascular endothelium and sensory nerves. This selectivity focuses the mechanism on the direct modulation of systemic processes; for instance, H1-R blockade on endothelial cells causes a reduction in capillary leakage, resulting in an adjustment to tissue fluid distribution. The mechanism exhibits long-term engagement due to the formation of the Desloratadine metabolite, which displays a prolonged affinity and binding time at the H1-R, driving continuous receptor occupancy and defining the prolonged effect profile.

Dosage and Administration Information

How to Use Lostop: Official Administration Guidelines

The administration of Lostop (Loratadine) follows standardized, once-daily regimens. The medicine is intended for the oral route of administration. It may be taken with or without food, providing flexibility in its daily timing.

Standard Dosing and Frequency

The core usage pattern is established on a once-daily schedule for continuous symptom management over 24 hours. The standard doses, which apply to various approved dosage forms (tablet, syrup, ODT), are based on age and weight:

Population Group Dosing Schedule Maximum Dose
Adults and Children ge 6 years (ge 30 kg) 10 mg once daily 10 mg per 24 hours
Children 2 to 5 years 5 mg once daily 5 mg per 24 hours

If a dose is missed, it should be taken as soon as it is remembered; however, a double dose should not be taken to compensate for the forgotten dose.

Population-Specific Use and Procedural Constraints

Specific adjustments are necessary for patients with pre-existing conditions. For adults and children weighing over 30 kg who have been diagnosed with severe hepatic or severe renal impairment (GFR <30 mL/min), the starting dose is reduced to 10 mg every other day.

Furthermore, Lostop administration must be discontinued for at least 48 hours before any planned skin allergy testing to ensure the accuracy of test results.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lostop (Loratadine)

The clinical evidence for Lostop is founded on Randomized Controlled Trials (RCTs) and systematic reviews that explored the effects of the medicine on symptoms related to allergic conditions. This research describes the structure of these studies, what they monitored, and where limitations are noted by regulatory authorities.

Evidence for Symptomatic Relief of Allergic Rhinitis (Hay Fever)

Research explored the evidence structure for allergic rhinitis, including both seasonal (hay fever) and perennial forms. Short-term RCTs typically monitored these conditions by examining outcomes related to symptom intensity, such as Total Symptom Scores (TSS) for nasal and ocular discomfort. Trials generally reported how symptoms evolved in the observed populations compared to placebo. Findings often describe patterns where data show a measured change in these symptom scores during the study period, although comparative research reported measurements of different outcomes compared to other anti-allergic agents.

Evidence for Symptomatic Management of Chronic Urticaria (Hives)

Controlled trials utilized to examine chronic idiopathic urticaria (CIU) explored outcomes related to physical discomfort. These studies monitored patient-reported outcomes describing perceived discomfort related to skin manifestations, specifically the severity and frequency of pruritus (itching) and the size of wheals (hives). Systematic reviews confirm that the active ingredient was observed in studies to have data show patterns related to these skin outcomes. Scientific literature reports that comparative evidence against every other medicine in this class is often limited.

Evidence for Non-Sedating Properties and Research Gaps

Specific clinical studies evaluated the impact of the medicine on functional measures to provide context on its profile. This research explored outcomes reflecting daily functioning, such as psychomotor performance. Studies reported that measurements of psychomotor and cognitive function were comparable to the findings reported for the placebo group. Research also included pharmacokinetic (PK) studies and short-term trials in young children (ages two to five years). However, regulators have explicitly noted that there is a relative paucity of long-term data regarding the maintenance of patient-reported outcomes over many months, especially for chronic conditions.

Key Studies & References

  1. Loratadine and Desloratadine Use in Children (Review citing PK studies in 2-5 year olds)

Frequently Asked Questions (FAQ)

Common questions about Lostop (FAQ)

Q: Is Lostop the same kind of medicine as [similar drug name]?

A: Lostop contains the active ingredient Loratadine, which is officially classified as a second-generation H₁-antihistamine. This categorization defines the medicine by its specific action on histamine receptors. Since many allergy medications belong to this same pharmacological class, they share a common intended use and general design.

Q: Does Lostop cause tiredness or make you drowsy?

A: Official information generally describes Lostop as a non-sedating antihistamine because it is designed to have limited effects on the brain. However, the regulatory labeling does list somnolence (drowsiness or tiredness) as a Common adverse reaction. It is generally described that individuals should be aware of their response to the medicine when starting treatment.

Q: Can Lostop affect my blood pressure?

A: Lostop (single-ingredient Loratadine) is not typically documented in official safety information as causing changes in blood pressure. However, regulatory authorities advise caution for patients who have pre-existing high blood pressure or heart disease, especially if the medicine is taken as a combination product that includes a decongestant. The official guidance emphasizes discussing any existing conditions with a healthcare provider.

Q: Is it common to have headaches when first starting Lostop?

A: Official safety data lists Headache as a Common adverse reaction, meaning it is reported in 1% to 10% of users across clinical trials. Official safety documents categorize side effects by overall frequency but do not typically detail the specific frequency of headaches only during the first few days of treatment.

Q: Does Lostop interact with supplements like St. John's Wort?

A: Lostop is broken down (metabolized) in the liver by specific enzymes. Authoritative sources often advise caution regarding substances that affect these enzymes. Supplements such as St. John’s Wort can interfere with these enzymes, potentially reducing the overall amount of Lostop in the body.

Q: Can I take Lostop if I have liver problems?

A: Official documents require caution for individuals with liver disease or hepatic impairment. For people with severe hepatic impairment, a specific dose adjustment is officially required to manage drug exposure. The official guidance emphasizes discussing any liver problems with a healthcare provider.

Q: How long does Lostop stay in your system after stopping it?

A: Lostop is engineered to provide long-lasting relief, primarily through its active metabolite, Desloratadine. This active substance has a prolonged elimination half-life of approximately 20 hours. Based on the prolonged half-life, it is described that the active substance can take approximately four to five days to be fully cleared from the body.

Q: How does Lostop's effectiveness compare to placebo in clinical trials?

A: The summary of clinical studies reported to regulatory bodies indicates that Lostop provided a measured change in symptom scores that was observed to be greater than the change reported in patients receiving a placebo. This was reported across studies for conditions like allergic rhinitis and chronic urticaria.

Q: Can Lostop make me feel anxious?

A: While the official labeling does not explicitly list 'Anxiety' among the most common adverse reactions, effects such as Nervousness (in children) and Insomnia (difficulty sleeping) are documented. These are classified within the category of Nervous System Disorders in official safety reports.

Q: Can Lostop affect my ability to drive (informational classification only)?

A: Due to the potential for somnolence (drowsiness) documented in official reports, the guidance indicates that individuals are encouraged to be aware of their personal response to the medicine before performing tasks that demand full mental alertness. This includes activities such as driving a vehicle or operating machinery.

Q: Are there any known food interactions with Lostop?

A: Official documents confirm that taking Lostop with food increases the systemic bioavailability (how much drug gets into the body) and delays the time it takes to reach peak plasma concentration. However, this change is not documented in official labeling as a clinically significant interaction that requires a mandatory change in when or how you eat.

Q: How long does it typically take to start feeling the effects of Lostop?

A: Clinical data reported to regulatory authorities indicates that the onset of action for allergy symptom relief typically begins within 1 to 3 hours after administration of the standard tablet form. This characteristic contributes to the medicine's profile for managing allergy symptoms.

Q: Is it possible for Lostop to stop working after a while?

A: Official regulatory documentation does not report the development of drug tolerance (a loss of effect known as tachyphylaxis) with continued use. Clinical literature often attributes observed worsening symptoms to the progression of the underlying allergic condition, rather than a loss of effect from the medication.

Q: Can Lostop cause weight changes?

A: Official safety documents list Appetite increased as an Uncommon adverse reaction, meaning it is reported in 0.1% to 1% of users. However, weight change itself is not explicitly listed as a separate, official adverse reaction category in the product labeling.

Q: What evidence exists about Lostop's use in children or adolescents?

A: Official clinical evidence presented to regulatory bodies includes both pharmacokinetic (PK) studies and short-term trials for use in children aged 2 to 5 years. There are also documented trials that have examined the efficacy and safety profile in older children and adolescents.

Q: Do studies suggest Lostop's effects are consistent across different age groups?

A: Regulatory documents note that while the drug's exposure may be increased in older adults due to natural changes in organ function, the general guidance states that no dose adjustment is required based on age alone. This suggests that the overall effect profile is considered generally consistent across adult age groups.

How should Lostop be stored and disposed of?

How to Store and Dispose of Lostop

Official regulatory guidelines mandate specific storage and disposal requirements for Loratadine (Lostop).

Storage Requirements

Item Requirement
Temperature Tablets/ODT: Store at Controlled Room Temperature, typically 20 C to 25 C. Oral Solution: Do not freeze.
Protection Keep the medication in the original container, tightly closed, and protect it from excessive heat and moisture.
Safety Store the medication strictly out of the reach of children.

Disposal Instructions

Expired or unused Lostop should be handled according to official pharmaceutical waste guidelines. The preferred disposal method is to take the product to an authorized drug take-back program. If this is unavailable, disposal in household trash must follow FDA-recommended procedures, which require mixing the product with an undesirable substance before sealing and discarding it. This medication is not advised to be flushed down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lostop found in:

A-Z Index: